• 1
    Jacob T., Usha R. (2001) 3′-Terminal sequence analysis of the RNA genome of the Indian isolate of cardamom mosaic virus: a new member of genus Maclura virus of potyviridae. Virus Genes 23: 818.
  • 2
    Atreya P.L., Atreya C.D., Pirone T.P. (1991) Amino acid substitutions in the coat protein result in loss of insect transmissibility of a plant virus. Proc Natl Acad Sci USA 88: 788791.
  • 3
    Dolja V.V., Haldeman-Cahill R., Montgomery A.E., Vandenbosch K.A., Carrington J.C. (1995) Capsid protein determinants involved in cell-to-cell and long distance movement of tobacco etch potyvirus. Virology 206: 100716.
  • 4
    Mahajan S., Dolja V.V., Carrington J.C. (1996) Roles of the sequence encoding tobacco etch virus capsid protein in genome amplification: requirements for the translation process and a cis-active element. J Virol 70: 43709.
  • 5
    Jagadish M.N., Ward C.W., Gough K.H., Tulloch P.A., Whittaker L.A., Shukla D.D. (1991) Expression of potyvirus coat protein in Escherichia coli and yeast and its assembly into virus-like particles. J Gen Virol 72: 154350.
  • 6
    Stram Y., Chetsrony A., Karchi H., Karchi M., Edelbaum O., Vardi E., Livneh O., Sela I. (1993) Expression of the “helper component” protein of potato virus Y (PVY) in E. coli : possible involvement of a third protease. Virus Genes 7: 1516.
  • 7
    Jagadish M.N., Huang D., Ward C.W. (1993) Site-directed mutagenesis of a potyvirus coat protein and its assembly in Escherichia coli. J Gen Virol 74: 8936.
  • 8
    Jagadish M.N., Hamilton R.C., Fernandez C.S., Schoofs P., Davern K.M., Kalnins H., Ward C.W., Nisbet I.T. (1993) High level production of hybrid potyvirus-like particles carrying repetitive copies of foreign antigens in Escherichia coli. Biotechnology 11: 116670.
  • 9
    Varrelmann M., Palkovics L., Maiss E. (2000) Transgenic or plant expression vector-mediated recombination of plum pox virus. J Virol 74: 74629.
  • 10
    Joseph J., Savithri H.S. (1999) Determination of 3′-terminal nucleotide sequence of pepper vein banding virus RNA and expression of its coat protein in Escherichia coli. Arch Virol 144: 167987.
  • 11
    Jacob T., Usha R. (2002) Expression of Cardamom mosaic virus coat protein in Escherichia coli and its assembly into filamentous aggregates. Virus Res 86: 13341.
  • 12
    Arazi T., Shiboleth Y.M., Gal on A. (2001) A nonviral peptide can replace the entire N terminus of Zucchini yellow mosaic potyvirus coat protein and permits viral systemic infection. J Virol 75: 632936.
  • 13
    Fernández-Fernández M.R., Martínez-Torrecuadrada J.L., Roncal F., Domínguez E., García J.A. (2002) Identification of immunogenic hot spots within Plum pox potyvirus capsid protein for efficient antigen presentation. J Virol 76: 1264653.
  • 14
    Kalnciema I., Skrastina D., Ose V., Pumpens P., Zeltins A. (2011) Potato virus Y-like particles as a new carrier for the presentation of foreign protein stretches. Mol Biotechnol 52: 12939.
  • 15
    Saini M., Vrati S. (2003) A Japanese encephalitis virus peptide present on Johnson grass mosaic virus-like particles induces virus-neutralizing antibodies and protects mice against lethal challenge. J Virol 77: 348794.
  • 16
    Choudhury S., Kakkar V., Suman P., Chakrabarti K., Vrati S., Gupta S.K. (2009) Immunogenicity of zona pellucida glycoprotein-3 and spermatozoa YLP12 peptides presented on Johnson grass mosaic virus-like particles. Vaccine 27: 294853.
  • 17
    Chatchen S., Juricek M., Rueda P., Kertbundit S. (2006) Papaya ringspot virus coat protein gene for antigen presentation in Escherichia coli. J Biochem Mol Biol 39: 1621.
  • 18
    Abacioglu Y.H., Fouts T.R., Laman J.D., Classen E., Pincus S.H., Moore J.P., Roby C.A., Kamin-Lewis R., Lewis G.K. (1994) Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. AIDS Res Hum Retrovir 10: 37181.
  • 19
    Vella C., Ferguson M., Dunn G., Meloen R., Langedijk H., Evans D., Minor P.D. (1993) Characterization and primary structure of a human immunodeficiency virus type 1 (HIV-1) neutralization domain as presented by a poliovirus type 1/HIV-1 chimera. J Gen Virol 74: 260307.
  • 20
    Cleveland S.M., McLain L., Cheung L., Jones T., Hollier M., Dimmock N.J. (2003) A region of the C-terminal tail of the gp41 envelope glycoprotein of human immunodeficiency virus type 1 contains a neutralizing epitope: evidence for its exposure on the surface of the virion. J Gen Virol 84: 591602.
  • 21
    Zwick M.B., Jensen R., Church S., Wang M., Stiegler G., Kunert R., Katinger H., Burton D.R. (2005) Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol 79: 125261.
  • 22
    Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Ruker F., Katinger H. (1993) A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 67: 66427.
  • 23
    Purtscher M., Trkola A., Gruber G., Buchacher A., Predl R., Steindl F., Tauer C., Berger R., Barrett N., Jungbauer A. (1994) A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retrovir 10: 16518.
  • 24
    Salzwedel K., West J.T., Hunter E. (1999) A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J Virol 73: 246980.
  • 25
    Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., Moore J.P., Stiegler G., Katinger H., Burton D.R., Parren P.W. (2001) Broadly neutralizing antibodies targeted to the membrane proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75(10): 892905.
  • 26
    Stiegler G., Kunert R., Purtscher M., Wolbank S., Voglauer R., Steindl F., Katinger H. (2001) A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retrovir 17: 175765.
  • 27
    Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., Burton D.R. (2004) Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 78: 1323252.
  • 28
    Jacob T. (2002) Investigations on the molecular biology of two phytopathogens: Cardamom mosaic virus and Erwinia amylovora. PhD thesis. Madurai Kamaraj University.
  • 29
    Ferrantelli F., Kitabwalla M., Rasmussen R.A., Cao C., Chou T.C., Katinger H., Stiegler G., Cavacini L.A., Bai Y., Cotropia J., Ugen K.E., Ruprecht R.M. (2004) Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies implications for acquired immunodeficiency syndrome vaccine. J Infect Dis 189: 714.
  • 30
    Xu W.D., Smith-Franklin B.A., Li P.L., Wood C., He J., Du Q.J., Bhat G.J., Kankasa C., Katinger H., Cavacini L.A., Posner M.R., Burton D.R., Chou T.C., Ruprecht R.M. (2001) Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B. J Hum Virol 4: 5561.
  • 31
    Bures R., Morris L., Williamson C., Ramjee G., Deers M., Fiscus S.A., Abdool-Karim S., Montefiori D.C. (2002) Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol 76: 223344.
  • 32
    Ramanathan V.D., Kumar M., Mahalingam J., Sathyamoorthy P., Narayanan P.R., Solomon S., Panicali D., Chakrabarty S., Cox J., Sayeed E., Ackland J., Verlinde C., Vooijs D., Loughran K., Barin B., Lombardo A., Gilmour J., Stevens G., Smith M.S., Tarragona-Fiol T., Hayes P., Kochhar S., Excler J.L., Fast P. (2009) A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses 25: 110716.
  • 33
    Broliden P.A., Von Gegerfelt A., Clapham P., Rosen J., Fenyo E.M., Wahren B., Broliden K. (1992) Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc Natl Acad Sci USA 89: 4615.
  • 34
    Dieltjens T., Heyndrickx L., Willems B., Gray E., Nieuwenhove L.V., Grupping K., Vanham G., Janssens W. (2009) Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies. Retrovirology 6: 113.
  • 35
    Pincus S.H., Messer K.G., Schwartz D.H., Lewis G.K., Graham B.S., Blattner W.A., Fisher G. (1993) Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. J Clin Invest 91: 198796.
  • 36
    Shen X., Parks R.J., Montefiori D.C., Kirchherr J.L., Keele B.F., Decker J.M., Blattner W.A., Gao F., Weinhold K.J., Hicks C.B., Greenberg M.L., Hahn B.H., Shaw G.M., Haynes B.F., Tomaras G.D. (2009) In vivo gp41 antibodies targeting the 2F5 mAb epitope mediate HIV-1 neutralization breadth. J Virol 83: 361725.
  • 37
    Ugen K.E., Goedert J.J., Boyer J., Refaeli Y., Frank I., Williams W.V., Willoughby A., Landesman S., Mendez H., Rubinstein A. (1992) Vertical transmission of human immunodeficiency virus (HIV) infection. Reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1. J Clin Investig 89: 192330.
  • 38
    Vella C., Minor P.D., Weller I.V.D., Jenkins O., Evans D., Almond J. (1991) Recognition of poliovirus/HIV chimeras by antisera from individuals with HIV infection. AIDS 5: 42530.
  • 39
    Hellen C.U., Kräusslich H.G., Wimmer E. (1989) Proteolytic processing of polyproteins in the replication of RNA viruses. Biochemistry 28: 988190.
  • 40
    Shukla D.D., Strike P.M., Tracy S.L., Gough K.H., Ward C.W. (1988) The N and C termini of the coat proteins of potyviruses are surface-located and the N terminus contains major virus-specific epitopes. J Gen Virol 69: 1497508.
  • 41
    Kalyan N.K., Lee S.G., Wilhelm J., Pisano M.R., Hum W.T., Hsiao C.L., Davis A.R., Eichberg J.W., Robert-Guroff M., Hung P.P. (1994) Immunogenicity of recombinant influenza virus haemagglutinin carrying peptides from the envelope protein of human immunodeficiency virus type 1. Vaccine 12: 75360.
  • 42
    Newton S.M.C., Joys T.M., Anderson S.A., Kennedy R.C., Hovi M.E., Stocker B.A.D. (1995) Expression and immunogenicity of an 18-residue epitope of HIV-1 gp41 inserted in the flagellar protein of a Salmonella live vaccine. Res Microbiol 146: 20316.
  • 43
    McLain L., Durrani Z., Wisniewski L.A., Porta C., Lomonossoff G.P., Dimmock N.J. (1996) Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus. Vaccine 14: 799810.
  • 44
    Cleveland S.M., Buratti E., Jones T.D., North P., Baralle F.E., McLain L., McInerney T.L., Durrani Z., Dimmock N.J. (2000) Immunogenic and antigenic dominance of a non-neutralizing epitope over a highly conserved neutralizing epitope in the gp41 transmembrane envelope glycoprotein of HIV-1: its deletion leads to a strong neutralizing antibody response. Virology 266: 6678.
  • 45
    Cleveland S.M., Jones T.D., Dimmock N.J. (2000) Properties of a neutralizing antibody that recognizes a conformational form of epitope ERDRD in the C-terminal tail of human immunodeficiency virus type 1. J Gen Virol 81: 125160.
  • 46
    Dimmock N.J. (2005) The complex antigenicity of a small external region of the C-terminal tail of the HIV-1 gp41 envelope protein: a lesson in epitope analysis. Rev Med Virol 15: 36581.
  • 47
    Heap C.J., Reading S.A., Dimmock N.J. (2005) An antibody specific for the C-terminal tail of gp41 of HIV-1 mediates post-attachment neutralization probably through inhibiting virus-cell fusion. J Gen Virol 86: 15019.
  • 48
    Coeffier E., Clement J.M., Cussac V., Khodaei-Boorane N., Jehanno M., Rojas M., Dridi A., Latour M., El Habib R., Barre-Sinoussi F., Hofnung M., Leclerc C. (2000) Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. Vaccine 19: 68493.
  • 49
    Ho J., Uger R.A., Zwick M.B., Luscher M.A., Barber B.H., MacDonald K.S. (2005) Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response. Vaccine 23: 155973.
  • 50
    Kusov Y.Y., Zamjatina N.A., Poleschuk V.F., Michailov M.I., Morace G., Eberle J., Gauss-Muller V. (2006) Immunogenicity of a chimeric hepatitis A virus (HAV) carrying the HIV gp41 epitope 2F5. Antivir Res 73: 10111.
  • 51
    Marusic C., Rizza P., Lattanzi L., Mancini C., Spada M., Belardelli F., Benvenuto E., Capone I. (2001) Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1. J Virol 75: 84349.
  • 52
    Muster T., Guinea R., Trkola A., Purtscher M., Klima A., Steindl F., Palese P., Katinger H. (1994) Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J Virol 68: 40314.
  • 53
    Zhang H., Huang Y., Fayad R., Spear G.T., Qiao L. (2004) Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine papillomavirus-HIV-1 gp41 chimeric virus-like particles. J Virol 78: 83428.
  • 54
    Wang Z., Liu Z., Cheng X., Chen Y.H. (2005) The recombinant immunogen with high-density epitopes of ELDKWA and ELDEWA induced antibodies recognizing both epitopes on HIV-1 gp41. Microbiol Immunol 49: 7039.
  • 55
    Moore P.L., Crooks E.T., Porter L., Zhu P., Cayanan C.S., Grise H., Corcoran P., Zwick M.B., Franti M., Morris L., Roux K.H., Burton D.R., Binley J.M. (2006) Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 80: 251528.
  • 56
    Alam S.M., Scearce R.M., Parks R., Plonk K., Plonk S.G., Sutherland L.L., Gorny M.K., Zolla-Pazner S., Vanleeuwen S., Moody M.A., Xia S.M., Montefiori D.C., Tomaras G.D., Weinhold K.J., Karim S.A., Hicks C.B., Liao H.X., Robinson J., Shaw G.M., Haynes B.F. (2008) Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. J Virol 82: 11525.
  • 57
    Haynes B.F., Fleming J., St. Clair E.W., Katinger H., Stiegler G., Kunert R., Robinson J., Scearce R.M., Plonk K., Staats H.F., Ortel T.L., Liao H.X., Alam S.M. (2005) Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308: 19068.
  • 58
    Erikstrup C., Kallestrup P., Zinyama-Gutsire R.B., Gomo E., Butterworth A.E., Pedersen B.K., Ostrowski S.R., Gerstoft J., Ullum H. (2007) Reduced mortality and CD4 cell loss among carriers of the interleukin-10-1082G allele in a Zimbabwean cohort of HIV-1-infected adults. AIDS 21: 228391.
  • 59
    Naicker D.D., Wang B., Losina E., Zupkosky J., Bryan S., Reddy S., Jaggernath M., Mokgoro M., Goulder P.J., Kaufmann D.E., Ndung'u T. (2011) Association of IL-10-promoter genetic variants with the rate of CD4 T-cell loss, IL-10 plasma levels, and breadth of cytotoxic T-cell lymphocyte response during chronic HIV-1 infection. Clin Infect Dis 54: 294302.
  • 60
    Shin H.D., Winkler C., Stephens J.C., Bream J., Young H., Goedert J.J., O'Brien T.R., Vlahov D., Buchbinder S., Giorgi J., Rinaldo C., Donfield S., Willoughby A., O'Brien S.J., Smith M.W. (2000) Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci USA 97: 14,46772.
  • 61
    Kollmann T.R., Pettoello-Mantovani M., Katopodis N.F., Hachamovitch M., Rubinstein A., Kim A., Goldstein H. (1996) Inhibition of acute in vivo human immunodeficiency virus infection by human interleukin 10 treatment of SCID mice implanted with human fetal thymus and liver. Proc Natl Acad Sci USA 93: 312631.
  • 62
    Malmgaard L. (2004) Induction and regulation of IFNs during viral infections. J Interferon Cytokine Res 24: 43954.
  • 63
    Pedroza-Martins L., Boscardin W.J., Anisman-Posner D.J., Redsar B.N., Bryson Y.J., Yang O.O., Uittenbogaart C.H. (2006) Interferon-[gamma] decreases replication of primary R5 HIV-1 isolates in thymocytes. AIDS 20: 93942.
  • 64
    Imami N., Antonopoulos C., Hardy G., Gazzard B., Gotch F. (1999) Assessment of type 1 and type 2 cytokines in HIV type 1-infected individuals: impact of highly active antiretroviral therapy. AIDS Res Hum Retro 15: 1499508.
  • 65
    Meyaard L., Hovenkamp E., Keet I., Hooibrink B., de Jong I., Otto S., Miedema F. (1996) Single cell analysis of IL-4 and IFN-gamma production by T cells from HIV-infected individuals: decreased IFN-gamma in the presence of preserved IL-4 production. J Immunol 157: 27128.
  • 66
    Rollenhagen C., Asin S.N. (2010) IL-8 decreases HIV-1 transcription in peripheral blood lymphocytes and ectocervical tissue explants. J Acquir Immune Defic Syndr 54: 4639.
  • 67
    Breen E., Rezai A., Nakajima K., Beall G., Mitsuyasu R., Hirano T., Kishimoto T., Martinez-Maza O. (1990) Infection with HIV is associated with elevated IL-6 levels and production. J Immunol 144: 4804.
  • 68
    Cocchi F., DeVico A., Garzino-Demo A., Arya S., Gallo R., Lusso P. (1995) Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270: 18115.
  • 69
    Cassaza J.P., Brenchley J.M., Hill B.J., Ayana R., Ambrozak D., Roderer M., Douek D.C., Betts M.R., Koup R.A. (2009) Autocrine production of β-chemokines protects CMV-specific CD4+ T cells from HIV infection. PLoS Pathog 5(10): e1000646. doi: 10.1371/journal.ppat.1000646